Progressive MS

2026 is upon us!  As fireworks ring out around the world to usher in the new year, we like to look ahead and think about what new developments we might see in multiple sclerosis research over the coming 12...

Research Update: ATA188 Phase 2 EMBOLD Study Today, Atara Biotherapeutics provided an update on their Phase 2 randomised clinical trial, called the EMBOLD study, which is testing the safety and effectiveness...

With the end of 2020 approaching (I don’t think anyone is going to miss it), we thought we would try out a new style of research update.  Generally, our articles are an in-depth look at a specific study...

Research Summary: Association of Initial Disease-Modifying With Later Conversion to Secondary Progressive Multiple Sclerosis In mid-January, we had the good fortune of getting to break some major multiple...

Research Summary: Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis Last week, during our Facebook Live Q&A, we discussed the potential role of Epstein-Barr Virus or EBV in...

Research Summary: Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis What is it? Ibudilast is an anti-inflammatory treatment, which also has effects that protect nerves.  It is thought to offer...

PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS Primary progressive multiple sclerosis (PPMS) is characterised by a steady worsening of disease or accumulation of disability from onset without any lengthy periods of...

PROGRESSIVE MULTIPLE SCLEROSIS AND MYELIN REPAIR We have seen an increasing number of powerful new treatments developed recently for relapsing remitting multiple sclerosis.  These treatments work in various...